Eli Lilly & Co. Gives 2014 Guidance; In Line with Analyst Estimates (LLY)

On Tuesday morning, Eli Lilly & Co. (LLY) gave EPS and revenue guidance for 2014, and LLY’s CEO and chairman made comments on the company’s strategy for the future.

Eli Lilly sees its EPS for the coming year in the range of $2.77 to $2.85; analysts’ estimates fall in the lower side of this range. The company sees 2014 revenue in the range of $19.2 billion to $19.8 billion, while The Street sees revenue coming in at $19.55 billion.

John C. Lechleiter, Ph.D., Lilly’s chairman, president and CEO, had the following comments about Lilly’s future performance and strategy: ”We continue to focus on the three strategic priorities that have guided our efforts throughout an extended period of patent expirations. First and foremost, we are replenishing and advancing our pipeline. Today, we have 13 potential new medicines in Phase III testing or submission stage, with 26 more in Phase II. We anticipate obtaining regulatory approvals for and successfully launching multiple products each year for the next few years. At the same time, we aim to sustain strong performance for our currently marketed brands and key growth areas. Finally, we continue to drive productivity gains across our business in order to adequately fund R&D, invest in the launch of new products, support necessary capital spending, engage in business development and return additional cash to shareholders through our dividend and our share repurchase program.”

Eli Lilly shares were inactive in pre-market trading. They finished yesterday up 43 cents, or 0.84%.